Trial Profile

An Open-label, Multi-center, Rollover Study in Subjects With Advanced Solid Tumor Malignancies After Participation in a Vopratelimab (JTX-2011) Clinical Study

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Vopratelimab (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Jounce Therapeutics

Most Recent Events

02 May 2024 Status changed from completed to discontinued since the sponsor decided to stop providing the study drug to patients who have been taking study treatment for more than two years.
28 Apr 2023 Status changed from active, no longer recruiting to completed.
09 Sep 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com